Thrasyvoulos Karydis

Co-founder, Chief Technology Officer, DeepCure

Is AI in Drug Discovery trapped in the data of the past?

Thras talks about removing biases from the DMTA cycle, and introduces an AI/design framework for identifying novel binding opportunities while taking into account ADME-tox profile and synthesizability. He walks you through how a robotic synthesis system opens up novel chemical spaces with reproducible multi-step synthesis from 100+ reaction types.

bio

Talks you might be also interested in

Karl-Heinz-Baringhaus_intro_1920x1080

Karl-Heinz Baringhaus

Sanofi

Grasping opportunities for better drug discovery: Interdisciplinarity, deeper insights into disease, new technologies and better decision-making

Watch Now
Josef-Eiblmaier_intro_1920x1080

Josef Eiblmaier

PharmaLex, a Cencora company

The beauty of heterogeneity versus the need for standardization: Enabling trusted data consumption in a multi-source, multi-ownership data landscape

Watch now
Nessa-Carson_intro_1920x1080

Nessa Carson

AstraZeneca

How not to waste a chemist's time: Chemical insights through great user experience

Watch now